Targeting the apicoplast in malaria

• Published in: Biochemical Society transactions Vol. 47; no. 4; p. 973
• Main Authors: Biddau, Marco, Sheiner, Lilach
• Format: Journal Article
• Language: English
• Published: England 30.08.2019
• Subjects: Animals; Antimalarials - pharmacology; Apicoplasts - drug effects; Apicoplasts - metabolism; Humans; Malaria - drug therapy; Malaria - parasitology; Oxidation-Reduction; Plasmodium - drug effects; Plasmodium - metabolism; Plasmodium; malaria; toxoplasma; apicoplast; drug; redox
• ISSN: 1470-8752
• DOI: 10.1042/BST20170563

Malaria continues to be one of the leading causes of human mortality in the world, and the therapies available are insufficient for eradication. Severe malaria is caused by the apicomplexan parasite Apicomplexan parasites, including the spp., are descendants of photosynthetic algae, and therefore they possess an essential plastid organelle, named the apicoplast. Since humans and animals have no plastids, the apicoplast is an attractive target for drug development. Indeed, after its discovery, the apicoplast was found to host the target pathways of some known antimalarial drugs, which motivated efforts for further research into its biological functions and biogenesis. Initially, many apicoplast inhibitions were found to result in 'delayed death', whereby parasite killing is seen only at the end of one invasion-egress cycle. This slow action is not in line with the current standard for antimalarials, which seeded scepticism about the potential of compounds targeting apicoplast functions as good candidates for drug development. Intriguingly, recent evidence of apicoplast inhibitors causing rapid killing could put this organelle back in the spotlight. We provide an overview of drugs known to inhibit apicoplast pathways, alongside recent findings in apicoplast biology that may provide new avenues for drug development.